Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.00 (0.00%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £18.86m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Re Agreement

26 Jun 2007 07:02

Phytopharm PLC26 June 2007 Company Contact: U.K. Investor Relations Contact:Phytopharm plc FDDr Daryl Rees CEO David YatesMr Piers Morgan CFO Ben Atwell+44 1480 437 697 +44 207 831 3113www.phytopharm.com Collaboration and Licence Agreement with The Beijing Institute for novel memoryand concentration product GODMANCHESTER, Cambridgeshire, U.K. (26 June 2007) - Phytopharm plc (LSE: PYM)("Phytopharm" or the "Company") announces today a Collaboration and LicenceAgreement with The Beijing Institute, Academy of Military Medical Sciences ("TheBeijing Institute") for the development of novel functional foods andpharmaceuticals, including a product for memory and concentration. Under the terms of the Collaboration and Licence Agreement, Phytopharm and TheBeijing Institute will collaborate to progress The Beijing Institute's leadproduct for memory and concentration selected from its library of patentedcompounds derived from Traditional Chinese Medicine. The Collaboration andLicence Agreement also extends to certain other patented compounds that may haveutility in other disease areas including vascular disorders and stroke.Phytopharm has been granted an exclusive licence from The Beijing Institute todevelop and commercialize these products globally in return for royalty andmilestone payments to The Beijing Institute upon the achievement of certainpre-defined goals. Financial terms of the agreement are not disclosed. Traditional Chinese Medicines have been used for thousands of years and overthat time a wealth of knowledge and expertise in the medicinal use of plants hasbuilt up. The Beijing Institute scientists have extensive knowledge ofTraditional Chinese Medicines and their research over the last 10 years has ledto the identification of a lead product that has the potential to improve memoryand concentration. Phytopharm will develop this lead product through furtherpre-clinical testing and progress into clinical trials. Commenting on today's announcement, Dr Xiaoming Yang, Head of The BeijingInstitute, said: "We are delighted to be working with Phytopharm and proud thatThe Beijing Institute's extensive expertise and experience in TraditionalChinese Medicine has been recognized by Phytopharm and we look forward to a longand fruitful collaboration." Commenting on today's announcement, Dr Daryl Rees, Chief Executive Officer ofPhytopharm, said: "We are excited about the Collaboration and Licence Agreementwith The Beijing Institute as it fulfils one of our strategic objectives ofexpanding our product portfolio with a novel functional food candidate formemory and concentration, an area in which we have established expertise. TheBeijing Institute's scientists bring significant knowledge on TraditionalChinese Medicine and we look forward to working with them to advance the leadproduct through clinical development." -Ends- Notes to Editors Phytopharm plc Phytopharm is a pharmaceutical development and functional food company whoseproduct leads are generated from medicinal plants. The Company's strategy is todevelop these products through 'proof of principle' clinical testing, and thensecure partners for late stage development, sales and marketing. Laboratory,manufacturing and clinical work is outsourced to selected specialists, operatingunder expert in-house management. This operational structure allows access tothe best external research facilities whilst maintaining low fixed overheads anda lower development cost structure. Beijing Institute The Beijing Institute (Institute of Radiation Medicine, the Academy of MilitaryMedical Sciences, Beijing) has over the past 50 years developed its researchstrengths from radiobiology into a wide range of scientific fields, includingbiotechnology, biochemistry, molecular biology, pharmaceutical chemistry,pharmacology, toxicology, experimental pathology, experimental haematology,genomics and proteomics. These groups were set up to provide the qualitycontrol for Traditional Chinese Medicine products and the identification anddevelopment of extracted active compounds. The Institutes considerableexpertise and experience in the extraction of active compounds from TraditionalChinese Medicine has resulted in several pharmaceutical products beingsuccessfully developed for the Chinese market. Functional Foods Functional foods are foodstuffs that provide health or physiological benefitsabove their nutritional value and have a health claim on the packaging.Currently gut and heart health products dominate with new interest in areas ofweight control, memory and concentration, immune system function and skinhealth. The global value of functional foods is estimated to be up to $65bn.The growth potential is predicted to be 50% from 2005-2010 with an acceleratingtrend for new products. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
4th Apr 20167:00 amRNSConsortium and Five Year Contract
31st Mar 20167:00 amRNSReal world study of Digital Biomarkers
31st Mar 20167:00 amRNSGrant of Awards to Directors
30th Mar 20167:00 amRNSNHS emergency and out-of-hours services contract
9th Mar 20169:30 amRNSEuropean research to tackle dementia
3rd Mar 20167:00 amRNSMehealth® used in American Academy of Pediatrics
1st Mar 201610:35 amRNSDirector/PDMR Shareholding
5th Feb 20167:00 amRNSDirector/PDMR Shareholding
4th Feb 20167:00 amRNSDirector/PDMR Shareholding
29th Jan 201610:45 amRNSResult of AGM
29th Jan 20167:00 amRNSAGM Statement
22nd Jan 20167:00 amRNSSelected for two NHS Innovation Test Beds
21st Jan 20167:00 amRNSMyBrainBook wins Regional Business Award
18th Jan 20167:00 amRNSFour contracts awarded worth over £3.0m
7th Jan 20167:00 amRNSFinancial Results for the year ended 30 Sept 2015
21st Dec 20152:03 pmRNSUpdate on Issued Share Capital
7th Dec 201510:04 amRNSResult of General Meeting
18th Nov 20153:45 pmRNSPublication of Circular
18th Nov 20157:00 amRNSProposed acquisition of Optimal Medicine & placing
2nd Nov 20153:38 pmRNSTotal Voting Rights
19th Oct 20157:00 amRNSPre-Close Trading Update
12th Oct 20151:16 pmRNSAdditional Listing
9th Oct 20157:00 amRNSCollaboration with leading pharmaceutical co in MS
2nd Oct 201511:18 amRNSExercise of Share Options
28th Aug 20157:00 amRNSIXICO awarded significant long-term contract
29th Jun 20157:00 amRNSVirtualScopics Alliance Update
25th Jun 20151:21 pmRNSHolding(s) in Company
26th May 20157:01 amRNSRelease of beta version of MyBrainBook®
12th May 20157:00 amRNSLaunch of UK Government funded project
30th Apr 20157:49 amRNSLaunch of dementia care digital platform
24th Apr 20157:00 amRNSNew contract in Huntington's disease
11th Mar 20157:00 amRNSVirtualScopics, IXICO and Micron in collaboration
6th Mar 201511:38 amRNSResult of AGM
10th Feb 20154:25 pmRNSReplacement - Financial Results
10th Feb 20157:00 amRNSResults for the 16 month period ended 30 Sept 2014
16th Jan 20157:00 amRNSIXICO selected as EPAD imaging analysis partner
16th Dec 20147:00 amRNSLicense of TrialTracker to VirtualScopics
26th Nov 20147:00 amRNSAnnouncement of enhanced contracts
29th Oct 20147:30 amRNSGrant of Awards to Directors
17th Sep 20147:00 amRNSAppointment of Chief Financial Officer
7th Aug 20147:00 amRNSAdditional Listing
31st Jul 20144:19 pmRNSHolding(s) in Company
21st Jul 20144:33 pmRNSDirector/PDMR Shareholding
18th Jul 20147:00 amRNSTrading Update
19th Jun 20147:00 amRNSCollaboration with the MRC for dementia research
6th Jun 20147:00 amRNSHalf Yearly Report
22nd May 20147:00 amRNSTwo contracts in Huntington's disease awarded
30th Apr 20142:58 pmRNSHolding(s) in Company
16th Apr 20147:00 amRNSIXICO plc announces SBRI Healthcare contract
20th Mar 201412:41 pmRNSResults of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.